• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1996 Fiscal Year Final Research Report Summary

Locoregional cancer chemotherapy of the esophageal cancer

Research Project

Project/Area Number 06671294
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionKagoshima University

Principal Investigator

AIKOU Takashi  Faculty of Medicine Kagoshima University, Professor, 医学部, 教授 (60117471)

Co-Investigator(Kenkyū-buntansha) BABA Masamichi  University Hospital, Kagoshima University, Assistant Professor, 医学部・附属病院, 講師 (60198950)
YOSHINAKA Heiji  University Hospital Kagoshima University, Associate Professor, 医学部・附属病院, 助教授 (80191625)
Project Period (FY) 1994 – 1996
KeywordsEsophageal cancer / Locoregional chemothrapy / BLM-SI / BLM-PLA / CDDP-MS
Research Abstract

We deviced three drug delivery systems : bleomycin adsorbed on silica particles (BLM-Sl), bleomycin incorporated into small cylinder of poly d, l-lactic acid (BLM-PLA) and cisplatin incorporated into poly lactic acid / polyethylene glycol acid blend microspheres (CDDP-MS). The results were as followes.
1) In a clinical pilot study for esophageal carcinoma, BLm-Sl or blemycin solution (BLM-SOL) was endoscopically injected into the esophageal wall prior to surgery. Bleomycin activity in the lymph nodes and connective tissues was significantly higher in BLM-Sl administration that those in BLM-SOL administration. Degenerative or necrotic changes were microscopically observed in 11 of 36 metastatic lymph nodes. Serious systemic side effects except for fever were not observed.
2) In the experimental study on the antitumor effect against Yoshida sarcoma in rats, BLM-PLA was superior to bleomycin solution in both drug distribution and antitumor effect.
3) In the experimental model of peritoneal dissemination in rats using Yoshida sarcoma, CDDP-MS was able to control malignant ascites without serious side effect compared with CDDP solution.
In conclusion, these three drug formes could be a useful modality for targeting chemotherapy.

  • Research Products

    (8 results)

All Other

All Publications (8 results)

  • [Publications] Natsugoe S.: "Ultrasonographic detection of lymph node metastasis in superficial carcinoma of the esophagus." Endoscopy. 28. 674-679 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Yoshizawa H.: "Cisplatin incorporated polylactide microspheres blending with water-soluble polymers." Proceed.Intern.Symp.Control.Rel.Bioact.Mater,. 381-382 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Shimada M.: "Enhanced efficacy of bleomycin adsorbed on silica particles against lymph node metastasis." Proceed.Intern.Symp.Control.Rel.Bioact.Mater.23. 387-388 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Tokuda K.: "In vivo activity of cisplatin microspheresincorporated with polylactic acid and polyethylene glycol acid." Proceed.Intern.Symp.Control.Rel.Bioact.Mater.385-386 (1996)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Natsugoe S.: "Ultrasonographic detection of lymph node metastasis in superficial carcinoma of the esophagus." Endoscopy. 28. 674-679 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Yoshizawa H.: "Cisplatin incorporated polylactide microspheres blending with water-soluble polymers. Proceed. Intern. Symp. Control. Rel. Bioact." Mater.381-382 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Shimada M.: "Enhanced efficacy of bleomycin adsorbed on silica particles against lymph node metastasis. Proceed. Intern. Symp. Control. Rel. Bioact." Mater.23. 387-388 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Tokuda K.: "In vivo activity of cisplatin microspheres incorporated with polylactic acid and polyethylene glycol acid. Proceed. Intern. Symp. Control. Rel. Bioact." Mater.385-386 (1996)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-03-09  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi